blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3973066

EP3973066 - GENE THERAPY VECTORS FOR INFANTILE MALIGNANT OSTEOPETROSIS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  25.02.2022
Database last updated on 15.06.2024
FormerThe international publication has been made
Status updated on  27.11.2020
Most recent event   Tooltip18.04.2024New entry: Decision on request for further processing 
Applicant(s)For all designated states
Spacecraft Seven, LLC
9 Cedar Brook Drive
Cranbury, NJ 08512 / US
[2022/13]
Inventor(s)01 / BEARD, Brian
c/o SPACECRAFT SEVEN, LLC
9 Cedar Brook Drive
Cranbury, New Jersey 08512 / US
02 / RICKS, David
c/o SPACECRAFT SEVEN, LLC
9 Cedar Brook Drive
Cranbury, New Jersey 08512 / US
03 / PRABHAKAR, Raj
c/o SPACECRAFT SEVEN, LLC
9 Cedar Brook Drive
Cranbury, New Jersey 08512 / US
 [2022/13]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/13]
Application number, filing date20809375.722.05.2020
[2022/13]
WO2020US34394
Priority number, dateUS201962852216P23.05.2019         Original published format: US 201962852216 P
[2022/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020237219
Date:26.11.2020
Language:EN
[2020/48]
Type: A1 Application with search report 
No.:EP3973066
Date:30.03.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 26.11.2020 takes the place of the publication of the European patent application.
[2022/13]
Search report(s)International search report - published on:US26.11.2020
(Supplementary) European search report - dispatched on:EP21.06.2023
ClassificationIPC:C12N15/86
[2022/13]
CPC:
A61K48/005 (EP,IL,US); C12N15/86 (EP,IL,KR,US); A61K48/00 (KR);
A61P19/00 (KR); C07K14/4702 (KR,US); C07K14/705 (EP,IL);
A01K2227/105 (EP,IL); A01K2267/0387 (EP,IL); C12N2740/16043 (EP,IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/13]
TitleGerman:GENTHERAPIEVEKTOREN FÜR INFANTILE MALIGNE OSTEOPETROSE[2022/13]
English:GENE THERAPY VECTORS FOR INFANTILE MALIGNANT OSTEOPETROSIS[2022/13]
French:VECTEURS DE THÉRAPIE GÉNIQUE POUR L'OSTÉOPÉTROSE MALIGNE INFANTILE[2022/13]
Entry into regional phase22.12.2021National basic fee paid 
22.12.2021Search fee paid 
22.12.2021Designation fee(s) paid 
22.12.2021Examination fee paid 
Examination procedure22.12.2021Examination requested  [2022/13]
15.04.2022Amendment by applicant (claims and/or description)
13.02.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
15.04.2024Request for further processing filed
15.04.2024Full payment received (date of receipt of payment)
Request granted
17.04.2024Decision despatched
Fees paidRenewal fee
14.03.2022Renewal fee patent year 03
14.03.2023Renewal fee patent year 04
13.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2007124578  (UNIV MONTREAL [CA], et al) [Y] 6 * abstract *;
 [A]WO2014035457  (NATURE TECHNOLOGY CORP [US], et al) [A] 1-3* abstract *;
 [Y]WO2018018958  (CARSGEN THERAPEUTICS CO LTD [CN]) [Y] 5 * abstract *;
 [XY]  - MOSCATELLI ILANA ET AL, "Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis", HUMAN GENE THERAPY, GB, (20180801), vol. 29, no. 8, doi:10.1089/hum.2017.053, ISSN 1043-0342, pages 938 - 949, XP093054052 [X] 4,7-15 * abstract * * page 939, column 1, paragraph 3 - page 941, column 2, paragraph 1 * * Figure S1; page 946, column 1, paragraph 2 - page 948 * [Y] 1-3,5,6

DOI:   http://dx.doi.org/10.1089/hum.2017.053
 [YD]  - THUDIUM CHRISTIAN SCHNEIDER ET AL, "Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis: Implications for Gene Therapy", CALCIFIED TISSUE INTERNATIONAL, NEW YORK, NY, US, vol. 99, no. 6, doi:10.1007/S00223-016-0187-6, ISSN 0171-967X, (20160819), pages 638 - 648, (20160819), XP036092823 [YD] 1-3 * abstract * * page 639, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1007/s00223-016-0187-6
 [AD]  - TOM DULL ET AL, "A Third-Generation Lentivirus Vector with a Conditional Packaging System", JOURNAL OF VIROLOGY, US, (19981101), vol. 72, no. 11, doi:10.1128/JVI.72.11.8463-8471.1998, ISSN 0022-538X, pages 8463 - 8471, XP055715204 [AD] 1-3 * abstract * * page 8464, column 14 *

DOI:   http://dx.doi.org/10.1128/JVI.72.11.8463-8471.1998
 [A]  - AARON E. CARNES ET AL, "Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields", THE JOURNAL OF GENE MEDICINE, (20101030), vol. 12, no. 10, doi:10.1002/jgm.1499, ISSN 1099-498X, pages 818 - 831, XP055079559 [A] 1-3 * abstract *

DOI:   http://dx.doi.org/10.1002/jgm.1499
 [A]  - GAËLLE VANDERMEULEN ET AL, "New Generation of Plasmid Backbones Devoid of Antibiotic Resistance Marker for Gene Therapy Trials", vol. 19, no. 11, doi:10.1038/MT.2011.182, ISSN 1525-0016, (20111101), pages 1942 - 1949, MOLECULAR THERAPY, ELSEVIER INC, US, URL: http://www.nature.com/mt/journal/v19/n11/full/mt2011182a.html, (20110830), XP002698168 [A] 1-3 * abstract * * page 1945, column 2, paragraph 3 - page 1946; figure 4 *

DOI:   http://dx.doi.org/10.1038/MT.2011.182
International search[Y]US2016215296  (WILLIAMS JAMES A [US]) [Y] 1-3 * Abstract; Claim 2; para [0011]; para [0021]; SEQ ID NO:20 *;
 [Y]US2017335344  (PAUZA CHARLES DAVID [US], et al) [Y] 3* Abstract; para [0123]; ; SEQ ID NO:25 *;
 [Y]  - MOSCATELLI et al., "Lentiviral gene transfer of TCIRG1 into peripheral blood CD 34+ cells restores osteoclast function in infantile malignant osteopetrosis", Bone, (20131100), vol. 57, no. 1, doi:10.1016/j.bone.2013.07.026, pages 1 - 9, XP028726722 [Y] 1-3 * . Abstract; *

DOI:   http://dx.doi.org/10.1016/j.bone.2013.07.026
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.